

HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

BYLVAY™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 855-856-5694

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Bylvay™ (odevixibat)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
PRURITUS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS			
1. Is the request by, or in consultation with, a hepatologist, gastroenterologist, or a physician that specializes in progressive familial intrahepatic cholestasis?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does the member have a diagnosis of progressive familial intrahepatic cholestasis with moderate-to-severe pruritus?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Is the diagnosis confirmed by documented genetic testing demonstrating a gene mutation affiliated with progressive familial intrahepatic cholestasis?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member have a serum bile acid concentration above the upper limit of the normal reference range?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Has the member tried and failed all of the following systemic therapies, unless contraindicated or intolerant: <ul style="list-style-type: none"> • cholestyramine • rifampicin • ursodiol • sertraline • phototherapy 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does the member have cirrhosis, portal hypertension, or history of a hepatic decompensation event (variceal hemorrhage, ascites, and hepatic encephalopathy)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a continued medical need for therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member experienced a positive clinical response to therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member have cirrhosis, portal hypertension, or history of a hepatic decompensation event (variceal hemorrhage, ascites, and hepatic encephalopathy)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-HU-126
 Origination Date: 01/01/2022
 Reviewed/Revised Date: 01/18/2023
 Next Review Date: 01/18/2024
 Current Effective Date: 02/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.